Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases

• Ngā kaituhi matua: Soo Min Jang (Author), Smitha Anam (Author), Tara Pringle (Author), Paul Lahren (Author), Sergio Infante (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2020-04-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment. However, its use is uncertain due to a lack of safety and efficacy o...